Moxifloxacin

Last updated

Moxifloxacin
Moxifloxacin.svg
Moxifloxacin-cation-from-xtal-3D-balls.png
Clinical data
Trade names Avelox, Vigamox, Moxiflox, others
Other namesMoxifloxacine; BAY 12-8039
AHFS/Drugs.com Monograph
MedlinePlus a600002
License data
Pregnancy
category
  • AU:B3
Routes of
administration 		By mouth, intravenous, eye drops
Drug class Antibiotic (fluoroquinolone)
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 86% [2]
Protein binding 47% [2]
Metabolism Glucuronide and sulfate conjugation; CYP450 Tooltip cytochrome P450 system not involved [3]
Elimination half-life 12.1 hours [2]
Excretion Urine, feces
Identifiers
  • 1-Cyclopropyl-7-[(1S,6S)-2,8-diazabicyclo[4.3.0]nonan-8-yl]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
NIAID ChemDB
CompTox Dashboard (EPA)
ECHA InfoCard 100.129.459 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C21H24FN3O4
Molar mass 401.438 g·mol−1
3D model (JSmol)
  • COc1c2c(cc(c1N3C[C@@H]4CCCN[C@@H]4C3)F)c(=O)c(cn2C5CC5)C(=O)O
  • InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1 Yes check.svgY
  • Key:FABPRXSRWADJSP-MEDUHNTESA-N Yes check.svgY
   (verify)

Moxifloxacin is an antibiotic, used to treat bacterial infections, [4] including pneumonia, conjunctivitis, endocarditis, tuberculosis, and sinusitis. [4] [5] It can be given by mouth, by injection into a vein, and as an eye drop. [5]

Contents

Common side effects include diarrhea, dizziness, and headache. [4] Severe side effects may include spontaneous tendon ruptures, nerve damage, and worsening of myasthenia gravis. [4] Safety of use in pregnancy and breastfeeding is unclear. [6] Moxifloxacin is in the fluoroquinolone family of medications. [4] It usually kills bacteria by blocking their ability to duplicate DNA. [4]

Moxifloxacin was patented in 1988 and approved for use in the United States in 1999. [7] [8] It is on the World Health Organization's List of Essential Medicines. [9] In 2022, it was the 273rd most commonly prescribed medication in the United States, with more than 800,000 prescriptions. [10] [11]

Medical uses

Moxifloxacin treats a number of infections, including respiratory-tract infections, bubonic plague, cellulitis, anthrax, intra-abdominal infections, endocarditis, meningitis, and tuberculosis. [12]

In the United States, moxifloxacin is licensed for the treatment of acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, complicated and uncomplicated infections of the skin and of the skin structure, and complicated intra-abdominal infections. [13] In the European Union, it is licensed for acute bacterial exacerbations of chronic bronchitis, non-severe community-acquired pneumonia, and acute bacterial sinusitis. On the basis of its investigation into reports of rare but severe cases of liver toxicity and skin reactions, the European Medicines Agency recommended in 2008 that the use of the oral (but not the intravenous) form of moxifloxacin be restricted to infections in which other antibacterial agents cannot be used or have failed. [14] In the United States, the marketing approval does not contain these restrictions, though the label contains prominent warnings of skin reactions.

The initial approval by the Food and Drug Administration of the United States (December 1999) [15] encompassed these indications:

Additional indications approved by the Food and Drug Administration:

The European Medicines Agency has advised that, for pneumonia, acute bacterial sinusitis, and acute exacerbations of COPD, it should only be used when other antibiotics are inappropriate. [20] [21]

Oral and intravenous moxifloxacin have not been approved for children. Several drugs in this class, including moxifloxacin, are not licensed by the Food and Drug Administration for use in children, because of the risk of permanent injury to the musculoskeletal system. [22] [23] [24] Moxifloxacin eye drops are approved for conjunctival infections caused by susceptible bacteria. [25]

Recently, alarming reports of moxifloxacin resistance rates among anaerobes have been published. In Austria 36% of Bacteroides have been reported to be resistant to moxifloxacin, [26] while in Italy resistance rates as high as 41% have been reported. [27]

Susceptible bacteria

A broad spectrum of bacteria is susceptible, including the following:

Adverse effects

Rare but serious adverse effects that may occur as a result of moxifloxacin therapy include irreversible peripheral neuropathy, spontaneous tendon rupture and tendonitis, [30] hepatitis, psychiatric effects (hallucinations, depression), torsades de pointes , Stevens–Johnson syndrome and Clostridioides difficile -associated disease, [31] and photosensitivity/phototoxicity reactions. [32] [33]

Several reports suggest the use of moxifloxacin may lead to uveitis. [34]

Pregnancy and breastfeeding

Exposure of the developing fetus to quinolones, including levofloxacin, during the first-trimester is not associated with an increased risk of stillbirths, premature births, birth defects, or low birth weight. [35] There is limited data about the appearance of moxifloxacin in human breastmilk. Animal studies have found that moxifloxacin appears in significant concentration in breastmilk. [36] Decisions as to whether to continue therapy during pregnancy or while breast feeding should take the potential risk of harm to the fetus or child into account, as well as the importance of the drug to the well-being of the mother. [37]

Contraindications

Only two listed contraindications are found within the 2008 package insert:

Though not stated as such within the package insert, ziprasidone is also considered to be contraindicated, as it may have the potential to prolong QT interval. Moxifloxacin should also be avoided in patients with uncorrected hypokalemia, or concurrent administration of other medications known to prolong the QT interval (antipsychotics and tricyclic antidepressants). [39]

Moxifloxacin should be used with caution in patients with diabetes, as glucose regulation may be significantly altered. [39]

Moxifloxacin is also considered to be contraindicated within the pediatric population, pregnancy, nursing mothers, patients with a history of tendon disorder, patients with documented QT prolongation, [40] and patients with epilepsy or other seizure disorders. Coadministration of moxifloxacin with other drugs that also prolong the QT interval or induce bradycardia (e.g., beta-blockers, amiodarone) should be avoided. Careful consideration should be given in the use of moxifloxacin in patients with cardiovascular disease, including those with conduction abnormalities. [39]

Children and adolescents

The safety of moxifloxacin in human patients under age 18 has not been established. Animal studies suggest a risk of musculoskeletal harm in juveniles. [37]

Interactions

Moxifloxacin is not believed to be associated with clinically significant drug interactions due to inhibition or stimulation of hepatic metabolism. Thus, it should not, for the most part, require special clinical or laboratory monitoring to ensure its safety. [41] Moxifloxacin has a potential for a serious drug interaction with NSAIDs. [42]

The combination of corticosteroids and moxifloxacin has increased potential to result in tendonitis and disability. [43]

Antacids containing aluminium or magnesium ions inhibit the absorption of moxifloxacin. Drugs that prolong the QT interval (e.g., pimozide) may have an additive effect on QT prolongation and lead to increased risk of ventricular arrhythmias. The international normalised ratio may be increased or decreased in patients treated with warfarin. [42]

Overdose

"In the event of acute overdose, the stomach should be emptied and adequate hydration maintained. ECG monitoring is recommended due to the possibility of QT interval prolongation. The patient should be carefully observed and given supportive treatment. The administration of activated charcoal as soon as possible after oral overdose may prevent excessive increase of systemic moxifloxacin exposure. About 3% and 9% of the dose of moxifloxacin, as well as about 2% and 4.5% of its glucuronide metabolite are removed by continuous ambulatory peritoneal dialysis and hemodialysis, respectively." (Quoting from 29 December 2008 package insert for Avelox) [38]

Pharmacology

Mechanism of action

Moxifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. It functions by inhibiting DNA gyrase, a type II topoisomerase, and topoisomerase IV, [44] enzymes necessary to separate bacterial DNA, thereby inhibiting cell replication.

Pharmacokinetics

About 52% of an oral or intravenous dose of moxifloxacin is metabolized via glucuronide and sulfate conjugation. The cytochrome P450 system is not involved in moxifloxacin metabolism, and is not affected by moxifloxacin. [3] The sulfate conjugate (M1) accounts for around 38% of the dose, and is eliminated primarily in the feces. Approximately 14% of an oral or intravenous dose is converted to a glucuronide conjugate (M2), which is excreted exclusively in the urine. Peak plasma concentrations of M2 are about 40% those of the parent drug, while plasma concentrations of M1 are, in general, less than 10% those of moxifloxacin. [38]

In vitro studies with cytochrome (CYP) P450 enzymes indicate that moxifloxacin does not inhibit 80 CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, suggesting that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these enzymes. [38] [3]

The pharmacokinetics of moxifloxacin in pediatric subjects have not been studied. [38]

The elimination half-life of moxifloxacin is 11.5 to 15.6 hours (single-dose, oral). [45] About 45% of an oral or intravenous dose of moxifloxacin is excreted as unchanged drug (about 20% in urine and 25% in feces). A total of 96 ± 4% of an oral dose is excreted as either unchanged drug or known metabolites. The mean (± SD) apparent total body clearance and renal clearance are 12 ± 2 L/h and 2.6 ± 0.5 L/h, respectively. [45] The CSF penetration of moxifloxacin is 70% to 80% in patients with meningitis. [46]

Chemistry

Moxifloxacin monohydrochloride is a slightly yellow to yellow crystalline substance. [38] It is synthesized in several steps, the first involving the preparation of racemic 2,8-diazabicyclo[4.3.0]nonane which is then resolved using tartaric acid. A suitably derivatised quinolinecarboxylic acid is then introduced, in the presence of DABCO, followed by acidification to form moxifloxacin hydrochloride. [47]

History

Moxifloxacin was first patented (United States patent) in 1991 by Bayer A.G., and again in 1997. [48] Avelox was subsequently approved by the U.S. Food and Drug Administration (FDA) for use in the United States in 1999 to treat specific bacterial infections. [7] Ranking 140th within the top 200 prescribed drugs in the United States for 2007, [49] Avelox generated sales of $697.3 million worldwide. [50]

Moxifloxacin is also manufactured by Alcon as Vigamox. [51]

Patent

A United States patent application was made on 30 June 1989, for Avelox, Bayer A.G. being the assignee, which was subsequently approved on 5 February 1991. This patent was scheduled to expire on 30 June 2009. However, this patent was extended for an additional two and one half years on 16 September 2004, and as such was not expected to expire until 2012. [52] Moxifloxacin was subsequently (ten years later) approved by the FDA for use in the United States in 1999. At least four additional United States patents have been filed regarding moxifloxacin hydrochloride since the 1989 United States application, [48] [53] as well as patents outside of the US.

Society and culture

Regulatory actions

Regulatory agencies have taken actions to address certain rare but serious adverse events associated with moxifloxacin therapy.[ citation needed ]

Based on its investigation into reports of rare but severe cases of liver toxicity and skin reactions, the European Medicines Agency recommended in 2008 that the use of the oral (but not the IV) form of moxifloxacin be restricted to infections in which other antibacterial agents cannot be used or have failed. [14] Similarly, the Canadian label includes a warning of the risk of liver injury. [54]

The U.S. label does not contain restrictions similar to the European label, but a carries a "black box" warning of the risk of tendon damage and/or rupture and warnings regarding the risk of irreversible peripheral neuropathy. [55]

Generic equivalents

In 2007, the U.S. District Court for the District of Delaware held that two Bayer patents on Avelox are valid and enforceable, and infringed by Dr. Reddy's ANDA for a generic version of Avelox. [56] [57] The district court sided with Bayer, citing the Federal Circuit's prior decision in Takeda v. Alphapharm [58] as "affirming the district court's finding that defendant failed to prove a prima facie case of obviousness where the prior art disclosed a broad selection of compounds, any one of which could have been selected as a lead compound for further investigation, and defendant did not prove that the prior art would have led to the selection of the particular compound singled out by defendant." According to Bayer's press release [56] announcing the court's decision, it was noted that Teva had also challenged the validity of the same Bayer patents at issue in the Dr. Reddy's case. Within Bayer's first-quarter 2008 stockholder's newsletter [59] Bayer stated that they had reached an agreement with Teva Pharmaceuticals USA, Inc., the adverse party, to settle their patent litigation with regard to the two Bayer patents. Under the settlement terms agreed upon, Teva would obtain a license to sell its generic moxifloxacin tablet product in the U.S. shortly before the second of the two Bayer patents expires in March 2014. In Bangladesh, it is available with brand name of Optimox.[ citation needed ]

Related Research Articles

<span class="mw-page-title-main">Amoxicillin</span> Beta-lactam antibiotic

Amoxicillin is an antibiotic medication belonging to the aminopenicillin class of the penicillin family. The drug is used to treat bacterial infections such as middle ear infection, strep throat, pneumonia, skin infections, odontogenic infections, and urinary tract infections. It is taken orally, or less commonly by either intramuscular injection or by an IV bolus injection, which is a relatively quick intravenous injection lasting from a couple of seconds to a few minutes.

<span class="mw-page-title-main">Ciprofloxacin</span> Fluoroquinolone antibiotic

Ciprofloxacin is a fluoroquinolone antibiotic used to treat a number of bacterial infections. This includes bone and joint infections, intra-abdominal infections, certain types of infectious diarrhea, respiratory tract infections, skin infections, typhoid fever, and urinary tract infections, among others. For some infections it is used in addition to other antibiotics. It can be taken by mouth, as eye drops, as ear drops, or intravenously.

<span class="mw-page-title-main">Clarithromycin</span> Antibiotic medication

Clarithromycin, sold under the brand name Biaxin among others, is an antibiotic used to treat various bacterial infections. This includes strep throat, pneumonia, skin infections, H. pylori infection, and Lyme disease, among others. Clarithromycin can be taken by mouth as a tablet or liquid or can be infused intravenously.

<span class="mw-page-title-main">Levofloxacin</span> Antibiotic

Levofloxacin, sold under the brand name Levaquin among others, is a broad-spectrum antibiotic of the fluoroquinolone drug class. It is the left-handed isomer of the medication ofloxacin. It is used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, H. pylori, urinary tract infections, Legionnaires' disease, chronic bacterial prostatitis, and some types of gastroenteritis. Along with other antibiotics it may be used to treat tuberculosis, meningitis, or pelvic inflammatory disease. It is available by mouth, intravenously, and in eye drop form.

<span class="mw-page-title-main">Ofloxacin</span> Antibiotic to treat bacterial infections

Ofloxacin is a quinolone antibiotic useful for the treatment of a number of bacterial infections. When taken by mouth or injection into a vein, these include pneumonia, cellulitis, urinary tract infections, prostatitis, plague, and certain types of infectious diarrhea. Other uses, along with other medications, include treating multidrug resistant tuberculosis. An eye drop may be used for a superficial bacterial infection of the eye and an ear drop may be used for otitis media when a hole in the ear drum is present.

<span class="mw-page-title-main">Cefprozil</span> Chemical compound

Cefprozil is a second-generation cephalosporin antibiotic. Originally discovered in 1983, and approved in 1992, it was sold under the tradename Cefzil by Bristol Meyers Squibb until 2010 when the brand name version was discontinued. It continues to be available from various companies in its generic form. It is used in the treatment of pharyngitis, tonsillitis, ear infections, acute sinusitis, bacterial exacerbation of chronic bronchitis, and skin and skin structure infections. It is currently available as a tablet and as a liquid suspension.

<span class="mw-page-title-main">Norfloxacin</span> Chemical compound, antibiotic

Norfloxacin, sold under the brand name Noroxin among others, is an antibiotic that belongs to the class of fluoroquinolone antibiotics. It is used to treat urinary tract infections, gynecological infections, inflammation of the prostate gland, gonorrhea and bladder infection. Eye drops were approved for use in children older than one year of age.

<span class="mw-page-title-main">Rifaximin</span> Antibiotic medication

Rifaximin, sold under the brand name Xifaxan among others, is a non-absorbable, broad-spectrum antibiotic mainly used to treat travelers' diarrhea. It is based on the rifamycin antibiotics family. Since its approval in Italy in 1987, it has been licensed in more than 30 countries for the treatment of a variety of gastrointestinal diseases like irritable bowel syndrome and hepatic encephalopathy. It acts by inhibiting RNA synthesis in susceptible bacteria by binding to the RNA polymerase enzyme. This binding blocks translocation, which stops transcription. It was developed by Salix Pharmaceuticals.

<span class="mw-page-title-main">Ciprofloxacin/dexamethasone</span> Pharmaceutical product

Ciprofloxacin/dexamethasone, sold under the brand name Ciprodex among others, is an antibiotic/steroid fixed-dose combination medication used for the treatment of ear infections. It contains ciprofloxacin, as the hydrochloride, a fluoroquinolone antibacterial; and dexamethasone, a corticosteroid. It is used as ear drops.

<span class="mw-page-title-main">Gemifloxacin</span> Medication to treat chronic bronchitis

Gemifloxacin mesylate, sold under the brand name Factive among others, is a broad-spectrum quinolone antibacterial agent used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is taken by mouth. Vansen Pharma Inc. licensed the active ingredient from LG Life Sciences of Korea.

<span class="mw-page-title-main">Dalbavancin</span> Antibiotic used to treat MRSA

Dalbavancin, sold under the brand names Dalvance in the US and Xydalba in the EU among others, is a second-generation lipoglycopeptide antibiotic medication. It belongs to the same class as vancomycin, the most widely used and one of the treatments available to people infected with methicillin-resistant Staphylococcus aureus (MRSA).

<span class="mw-page-title-main">Flumequine</span> Chemical compound

Flumequine is a synthetic fluoroquinolone antibiotic used to treat bacterial infections. It is a first-generation fluoroquinolone antibacterial that has been removed from clinical use and is no longer being marketed. The marketing authorization of flumequine has been suspended throughout the EU. It kills bacteria by interfering with the enzymes that cause DNA to unwind and duplicate. Flumequine was used in veterinarian medicine for the treatment of enteric infections, as well as to treat cattle, swine, chickens, and fish, but only in a limited number of countries. It was occasionally used in France to treat urinary tract infections under the trade name Apurone. However this was a limited indication because only minimal serum levels were achieved.

<span class="mw-page-title-main">Prulifloxacin</span> Chemical compound

Prulifloxacin is an older synthetic antibiotic of the fluoroquinolone class undergoing clinical trials prior to a possible NDA submission to the U.S. Food and Drug Administration (FDA). It is a prodrug which is metabolized in the body to the active compound ulifloxacin. It was developed over two decades ago by Nippon Shinyaku Co. and was patented in Japan in 1987 and in the United States in 1989.

<span class="mw-page-title-main">Clinafloxacin</span> Chemical compound

Clinafloxacin is an investigational fluoroquinolone antibiotic. Despite its promising antibiotic activity, the clinical development of clinafloxacin has been hampered by its risk for inducing serious side effects.

<span class="mw-page-title-main">Tedizolid</span> Oxazolidinone-class antibiotic

Tedizolid, sold under the brand name Sivextro is an oxazolidinone-class antibiotic. Tedizolid phosphate is a phosphate ester prodrug of the active compound tedizolid. It was developed by Cubist Pharmaceuticals, following acquisition of Trius Therapeutics, and is marketed for the treatment of acute bacterial skin and skin structure infections.

<span class="mw-page-title-main">Antibiotic misuse</span> Improper use of antibiotic medications

Antibiotic misuse, sometimes called antibiotic abuse or antibiotic overuse, refers to the misuse or overuse of antibiotics, with potentially serious effects on health. It is a contributing factor to the development of antibiotic resistance, including the creation of multidrug-resistant bacteria, informally called "super bugs": relatively harmless bacteria can develop resistance to multiple antibiotics and cause life-threatening infections.

<span class="mw-page-title-main">Solithromycin</span> Chemical compound

Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia and other infections.

<span class="mw-page-title-main">Quinolone antibiotic</span> Class of antibacterial drugs, subgroup of quinolones

Quinolone antibiotics constitute a large group of broad-spectrum bacteriocidals that share a bicyclic core structure related to the substance 4-quinolone. They are used in human and veterinary medicine to treat bacterial infections, as well as in animal husbandry, specifically poultry production.

<span class="mw-page-title-main">Omadacycline</span> Chemical compound

Omadacycline, sold under the brand name Nuzyra, is a broad spectrum antibiotic medication belonging to the aminomethylcycline subclass of tetracycline antibiotics. In the United States, it was approved in October 2018, for the treatment of community-acquired bacterial pneumonia and acute skin and skin structure infections.

<span class="mw-page-title-main">Finafloxacin</span> Chemical compound

Finafloxacin (Xtoro) is a fluoroquinolone antibiotic. In the United States, it is approved by the Food and Drug Administration to treat acute otitis externa caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.

References

  1. ↑ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA . Retrieved 22 October 2023.
  2. 1 2 3 Zhanel GG, Fontaine S, Adam H, Schurek K, Mayer M, Noreddin AM, et al. (2006). "A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections". Treatments in Respiratory Medicine. 5 (6): 437–465. doi:10.2165/00151829-200605060-00009. PMID   17154673. S2CID   26955572.
  3. 1 2 3 World Health Organization (2008). Guidelines for the Programmatic Management of Drug-resistant Tuberculosis. World Health Organization. pp. 189–. ISBN   978-92-4-154758-1.
  4. 1 2 3 4 5 6 "Moxifloxacin Hydrochloride". The American Society of Health-System Pharmacists. Retrieved 29 August 2017.
  5. 1 2 British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. pp. 408, 757. ISBN   9780857111562.
  6. ↑ "Moxifloxacin Use During Pregnancy". Drugs.com. Retrieved 10 December 2017.
  7. 1 2 "Details for NDA:021085". DrugPatentWatch. Retrieved 17 July 2009.
  8. ↑ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 501. ISBN   9783527607495.
  9. ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl: 10665/371090 . WHO/MHP/HPS/EML/2023.02.
  10. ↑ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  11. ↑ "Moxifloxacin Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
  12. ↑ "Avelox". The American Society of Health-System Pharmacists. Retrieved 3 April 2011.
  13. ↑ "Documents" (PDF). accessdata.fda.gov.
  14. 1 2 "Press release" (PDF). Europa (web portal).
  15. ↑ "Application letter" (PDF). accessdata.fda.gov. 1999. Retrieved 7 June 2019.
  16. ↑ "Approval of supplements" (PDF). accessdata.fda.gov. 2001. Retrieved 7 June 2019.
  17. ↑ "Application letter" (PDF). accessdata.fda.gov. 2004. Retrieved 7 June 2019.
  18. ↑ "Approval of supplements" (PDF). accessdata.fda.gov. 2005. Retrieved 7 June 2019.
  19. ↑ "Application letter" (PDF). accessdata.fda.gov. Retrieved 7 June 2019.
  20. ↑ "Moxifloxacin: increased risk of life-threatening liver reactions and other serious risks". gov.uk. Retrieved 8 February 2022.
  21. ↑ "European Medicines Agency recommends restricting the use of oral moxifloxacin-containing medicines" (PDF). European Medicines Agency. 24 July 2008. Archived from the original (PDF) on 8 July 2009. Retrieved 20 July 2009.
  22. ↑ "SYNOPSIS" (PDF). Retrieved 29 January 2009.
  23. ↑ Karande SC, Kshirsagar NA (February 1992). "Adverse drug reaction monitoring of ciprofloxacin in pediatric practice". Indian Pediatrics. 29 (2): 181–188. PMID   1592498.
  24. ↑ Dolui SK, Das M, Hazra A (2007). "Ofloxacin-induced reversible arthropathy in a child". Journal of Postgraduate Medicine. 53 (2): 144–145. doi: 10.4103/0022-3859.32220 . PMID   17495385.
  25. ↑ "Center for drug evaluation and research Application number 21-598" (PDF). Food and Drug Administration (FDA). 15 April 2005. Retrieved 21 July 2009.
  26. ↑ König E, Ziegler HP, Tribus J, Grisold AJ, Feierl G, Leitner E (April 2021). "Surveillance of Antimicrobial Susceptibility of Anaerobe Clinical Isolates in Southeast Austria: Bacteroides fragilis Group Is on the Fast Track to Resistance". Antibiotics. 10 (5): 479. doi: 10.3390/antibiotics10050479 . PMC   8143075 . PMID   33919239.
  27. ↑ Principe L, Sanson G, Luzzati R, Aschbacher R, Pagani E, Luzzaro F, Di Bella S (August 2022). "Time to reconsider moxifloxacin anti-anaerobic activity?". Journal of Chemotherapy. 35 (4): 367–368. doi:10.1080/1120009X.2022.2106637. PMID   35947127. S2CID   251470489.
  28. ↑ Unemo M, Jensen JS (March 2017). "Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium". Nature Reviews. Urology. 14 (3): 139–152. doi:10.1038/nrurol.2016.268. PMID   28072403. S2CID   205521926.
  29. ↑ Pothineni VR, Wagh D, Babar MM, Inayathullah M, Solow-Cordero D, Kim KM, et al. (1 April 2016). "Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening". Drug Design, Development and Therapy. 10: 1307–1322. doi: 10.2147/DDDT.S101486 . PMC   4827596 . PMID   27103785.
  30. ↑ Albrecht R (28 July 2004). "NDA 21-085/S-024, NDA 21-277/S-019" (PDF). Center for Drug Evaluation and Research. Food and Drug Administration (FDA). Retrieved 31 July 2009.
  31. ↑ Albrecht R (31 May 2007). "NDA 21-085/S-036, NDA 21-277/S-030" (PDF). Center for Drug Evaluation and Research. Food and Drug Administration (FDA). Retrieved 31 July 2009.
  32. ↑ Albrecht R (15 February 2008). "NDA 21-085/S-038, NDA 21-277/S-031" (PDF). Division of Special Pathogen and Transplant Products. Food and Drug Administration (FDA). Retrieved 31 July 2009.
  33. ↑ DEPARTMENT OF HEALTH & HUMAN SERVICES (28 February 2008). "NDA 21-085/S-014, S-015, S-017" (PDF). Food and Drug Administration (FDA). Retrieved 17 July 2009.
  34. ↑ "Risk for Uveitis With Oral Moxifloxacin". JAMA Ophthalmology online. 2 October 2014.
  35. ↑ Ziv A, Masarwa R, Perlman A, Ziv D, Matok I (March 2018). "Pregnancy Outcomes Following Exposure to Quinolone Antibiotics - a Systematic-Review and Meta-Analysis". Pharmaceutical Research. 35 (5): 109. doi:10.1007/s11095-018-2383-8. PMID   29582196. S2CID   4724821.
  36. ↑ Balfour JA, Lamb HM (January 2000). "Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections". Drugs. 59 (1): 115–139. doi:10.2165/00003495-200059010-00010. PMID   10718103. S2CID   195694147.
  37. 1 2 "merck.com" (PDF).
  38. 1 2 3 4 5 6 7 Bayer (December 2008). "AVELOX (moxifloxacin hydrochloride) Tablets AVELOX I.V. (moxifloxacin hydrochloride in sodium chloride injection)" (PDF). Food and Drug Administration (FDA). p. 19. Retrieved 2 November 2010.
  39. 1 2 3 "Moxifloxacin". University of Maryland Medical Center. 2009. Archived from the original on 7 March 2009. Retrieved 22 July 2009.
  40. ↑ "Microsoft Word - Rote Hand Brief Avalox an BfArM.doc" (PDF). Retrieved 7 June 2019.
  41. ↑ Nightingale CH (March 2000). "Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics". Pharmacotherapy. 20 (3): 245–256. doi:10.1592/phco.20.4.245.34880. PMID   10730681. S2CID   11448163.
  42. 1 2 U.S. Food and Drug Administration (15 December 1999). "RE: NDA # 21-085 Avelox (moxifloxacin hydrochloride) Tablets MACMIS # 8577" (PDF). Letter to Martina Ziska. Archived from the original (PDF) on 9 March 2009. Retrieved 11 April 2009.
  43. ↑ Albrecht R (16 May 2002). "NDA 21-085/S-012" (PDF). Food and Drug Administration (FDA). Retrieved 17 July 2009.
  44. ↑ Drlica K, Zhao X (September 1997). "DNA gyrase, topoisomerase IV, and the 4-quinolones". Microbiology and Molecular Biology Reviews. 61 (3): 377–392. doi:10.1128/mmbr.61.3.377-392.1997. PMC   232616 . PMID   9293187.
  45. 1 2 "Drug card for Moxifloxacin (DB00218)". Canada: DrugBank. 19 February 2009. Retrieved 3 August 2009.
  46. ↑ Alffenaar JW, van Altena R, Bökkerink HJ, Luijckx GJ, van Soolingen D, Aarnoutse RE, van der Werf TS (October 2009). "Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis". Clinical Infectious Diseases. 49 (7): 1080–1082. doi: 10.1086/605576 . hdl: 2066/79494 . PMID   19712035.
  47. ↑ Peterson U (2006). "Quinolone Antibiotics: The Development of Moxifloxacin". In Fischer J, Ganellin CR (eds.). Analogue-based Drug Discovery. John Wiley & Sons. pp. 338–342. ISBN   9783527607495.
  48. 1 2 "Inventors/Applicants". patentlens.net. 3 October 2006. Archived from the original on 21 February 2013. Retrieved 17 July 2009.
  49. ↑ Lamb E (1 May 2008). "Top 200 Prescription Drugs of 2007". Pharmacy Times. Archived from the original on 7 February 2009. Retrieved 21 July 2009.
  50. ↑ "EU agency recommends restricting moxifloxacin use". Reuters. 24 July 2008. Retrieved 21 July 2009.
  51. ↑ "Alcon's Newest Antibiotic, Vigamox Ophthalmic Solution, Earns FDA Approval". Infection Control Today. Alcon. 22 June 2003. Archived from the original on 16 August 2016. Retrieved 25 June 2016.
  52. ↑ "Patent form" (PDF). uspto.gov. 1 February 1991. Retrieved 7 June 2019.
  53. ↑ US 4990517 A (Feb 1991) Petersen et al. See US 5051509 A (Sep 1991) Nagano et al. See US 5059597 A (Oct 1991) Petersen et al. See US 5395944 A (Mar 1995) Petersen et al. See US 5416096 A (May 1995) Petersen et al. See
  54. ↑ "Updated Labelling for Antibiotic Avelox (Moxifloxacin) Regarding Rare Risk of Severe Liver Injury". Health Canada. 22 March 2010. Information Update: 2010-42
  55. ↑ Albrecht R (3 October 2008). "NDA 21-085/S-040, NDA 21-277/S-034" (PDF). Center for Drug Evaluation and Research. Food and Drug Administration. Retrieved 31 July 2009.
  56. 1 2 Bayer AG (6 November 2007). "Ruling in Bayer's favor over Avelox patents". Bayer. Archived from the original on 11 December 2008. Retrieved 29 August 2009.
  57. ↑ "Opinion form" (PDF). orangebookblog.com. 5 October 2007. Retrieved 7 June 2019.
  58. ↑ "United States Court of Appeals for the Federal Circuit" (PDF). uscourts.gov. 28 June 2007. Archived from the original (PDF) on 26 August 2009. Retrieved 29 August 2009.
  59. ↑ Bayer AG (24 April 2008). "Risk Report". Bayer. Archived from the original on 9 March 2009. Retrieved 29 August 2009.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.